Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae
Health Sciences AUS · 2025
DOI: 10.70765/ebx1qj96 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Sciences AUS, 2025. Verfasst von Dr Annas Sani. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Acne keloidalis nuchae (AKN) is a chronic, scarring folliculitis that predominantly affects the occipital scalp and posterior neck, leading to significant cosmetic and psychological morbidity. Current treatment remains challenging, and recurrence is common.
Objective
This article reviews the efficacy and safety of intralesional triamcinolone acetonide (ILTA) in AKN and presents clinical insights into its application as a practical, cost-effective therapy.
Methods
A comprehensive review of the literature was undertaken using PubMed, Google Scholar, and regional databases. In addition, case experiences from patients treated with ILTA injections at a dermatology practice in Pakistan are highlighted.
Results
ILTA demonstrates significant efficacy in reducing inflammation, pruritus, and lesion size, with high patient satisfaction. Side effects such as atrophy and hypopigmentation are rare when administered at appropriate concentrations. Combination approaches (ILTA with antibiotics, laser, or surgery) further improve long-term outcomes.
Conclusion
ILTA is a cornerstone therapy for AKN, offering a safe and effective treatment option when delivered using proper technique and dosage.
Zitieren
APA
Sani, D. A. (2025). Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae. Health Sciences AUS. https://doi.org/10.70765/ebx1qj96
Vancouver
Sani DA. Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae. Health Sciences AUS. 2025. doi:10.70765/ebx1qj96
BibTeX
@article{Sani2025,
author = {Sani, Dr Annas},
title = {Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae},
journal = {Health Sciences AUS},
year = {2025},
doi = {10.70765/ebx1qj96}
}
EUVIMED